Divestiture • Life Science

Servier Acquires CTI BioPharma - PIXUVRI

On October 1, 2019, Servier acquired life science company CTI BioPharma - PIXUVRI from CTI BioPharma

Acquisition Context
  • This is Servier’s 1st transaction in the Life Science sector.
  • This is Servier’s 1st transaction in the United States.
  • This is Servier’s 1st transaction in Washington.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date October 1, 2019
Target CTI BioPharma - PIXUVRI
Sector Life Science
Buyer(s) Servier
Sellers(s) CTI BioPharma
Deal Type Divestiture

Target Company

CTI BioPharma - PIXUVRI

Seattle, Washington, United States
CTI BioPharma Corp. - PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Servier

Suresnes, France

Category Company
Founded 1954
Sector Life Science
Employees22,000
Revenue 4.2B EUR (2018)
DESCRIPTION

Servier is a pharmaceutical company governed by a non-profit foundation. Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. Servier was founded in 1954 and is based in Suresnes, France.


Deal Context for Buyer #
Overall 1 of 3
Sector: Life Science 1 of 3
Type: Divestiture 1 of 2
State: Washington 1 of 1
Country: United States 1 of 2
Year: 2019 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-04 Symphogen AS

Ballerup, Denmark

Symphogen AS is a polyclonal antibody technology that provides a totally new, innovative class of biopharmaceuticals for treating serious human diseases. Symphogen was founded in 2000 and is based in Ballerup, Denmark.

Buy -

Seller Profile 1

SELLER

CTI BioPharma

Seattle, Washington, United States

Category Company
Founded 1991
Sector Life Science
Employees144
Revenue 54M USD (2022)
DESCRIPTION

CTI is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI BioPharma was founded in 1991 and is based in Seattle, Washington.


Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
State: Washington 1 of 1
Country: United States 1 of 1
Year: 2019 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-07-31 Systems Medicine

Tucson, Arizona, United States

Systems Medicine, Inc. is a privately held oncology company produces oncology products.

Buy -